- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01007357
Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation
July 12, 2023 updated by: University of Nebraska
This project will facilitate the optimization of body MR imaging at 3 Tesla.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
This project is meant to improve the image quality of multiple sequences at 3.0T applied to the abdominal and pelvic regions.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, United States, 68198-1045
- University of Nebraska Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Subjects between ages of 19 and 65
- Healthy volunteer subjects should not have any history of disease or symptoms - based on clinical history
- Subjects with an underlying disorder (diffuse and focal abnormalities of the liver and pancreas)
Exclusion Criteria:
- Inability to provide informed consent
- A medical or contraindications that will prevent subjects from having a MRI
- Subjects with severe renal dysfunction or patients on dialysis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Body MRI healthy volunteers
Body MRI to optimize sequences in healthy individuals and in disorder subjects
|
Body MR imaging will be performed to optimize sequences
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Optimizing body MR imaging sequences
Time Frame: 2 years
|
Healthy volunteers will be used to obtain optimized body MR imaging sequences that will then be used to evaluate MR imaging sequences of subjects with underlying disorders.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Shahid Hussain, MD, University of Nebraska
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2009
Primary Completion (Actual)
June 30, 2015
Study Completion (Actual)
June 30, 2015
Study Registration Dates
First Submitted
October 28, 2009
First Submitted That Met QC Criteria
November 3, 2009
First Posted (Estimated)
November 4, 2009
Study Record Updates
Last Update Posted (Actual)
July 14, 2023
Last Update Submitted That Met QC Criteria
July 12, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0290-09-FB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse and Focal Abnormalities of the Liver and Pancreas
-
Université de SherbrookeCentre hospitalier de l'Université de Montréal (CHUM); Réseau de bio-imagerie...CompletedDiffuse and Focal Liver Diseases, Cerebral FunctionCanada
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Shandong Provincial Hospital; Liaocheng... and other collaboratorsRecruitingThe Malignant Lesions and Non-malignant Lesions of Pancreas, Bile Duct, Liver and Lymph NodeChina
-
Societatea Romana de Ultrasonografie in Medicina...Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian... and other collaboratorsUnknownLiver Metastases | Focal Nodular Hyperplasia of Liver | Toxic Liver Disease With Focal Nodular HyperplasiaRomania
-
Karolinska University HospitalKarolinska InstitutetCompletedBenign Neoplasm of Liver and/or Biliary Ducts | Neoplasm of Uncertain Behavior of Biliary System | Benign Neoplasms of the Pancreas | Neoplasms of the PancreasSweden
-
University of FloridaCompletedDisorders of the Pancreas and Biliary TreeUnited States
-
Peking Union Medical College HospitalRecruitingPancreas Cancer | Solid Pseudopapillary Tumor of the PancreasChina
-
Centre Leon BerardMerck Sharp & Dohme LLC; Debiopharm International SACompletedAdenocarcinoma of the Pancreas | Adenocarcinoma of the Rectum | Adenocarcinoma of the ColonFrance
-
Samyang Biopharmaceuticals CorporationUnknownMetastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the PancreasKorea, Republic of
-
Washington University School of MedicineCompletedPancreatic Cancer | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the PancreasUnited States
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.; Teva PharmaCompletedAdenocarcinoma of the Pancreas | Solid Tumour | Adenocarcinoma of the Colorectal
Clinical Trials on Body MR imaging
-
National Institute of Diabetes and Digestive and...RecruitingHealthy | Obesity | Diabetes | Atherosclerosis | Healthy VolunteersUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnRenal Cell Carcinoma | Stage I Renal Cell Cancer AJCC v8 | Stage II Renal Cell Cancer AJCC v8United States
-
Cedars-Sinai Medical CenterWithdrawnCoronary Artery Disease | CancerUnited States
-
Manchester University NHS Foundation TrustCompletedNeurofibromatosis Type 2United Kingdom
-
Children's Hospital of PhiladelphiaCompleted
-
Stanford UniversityThe American Association of Physicists in MedicineTerminatedPancreatic Cancer | Lung Cancer | Liver Cancer | Hepatobiliary Cancers | Hepatobiliary Cancers Liver | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC) | Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma) | Hepatobiliary Cancers Gallbladder | Hepatobiliary Cancers...United States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsCompletedCardiovascular Diseases | HIV/AIDS | Transgender Women | Coagulopathy | Metabolic DiseaseUnited States
-
Turku University HospitalCompletedBladder CancerFinland
-
University of ZurichCompletedNerve DegenerationSwitzerland
-
Assistance Publique Hopitaux De MarseilleCompleted